logo

For the Inventor, By the Inventor

Mechelen, Belgium

Martin James Inglis Andrews

This inventor holds 16 USPTO granted patents and 3 published patent applications and 4 EPO patents. Top assignees: Galapagos Nv, Janssen Pharmaceutica Nv. Active years: 2009-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin James Inglis Andrews. Retrieved from https://idiyas.com/inventor/martin-james-inglis-andrews

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 

% Patents Active = 50.0

 

Average Co-Inventor Count = 6.3

ph-index = 4

Forward Citations = 38(Granted Patents)


Company Filing History:

goldMedal9 out of 116 
 
Galapagos Nv
 patents
silverMedal7 out of 2,101 
 
Janssen Pharmaceutica Nv
 patents

Years Active: 2009-2020

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 10568867 - Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis (2020-02-25),
2. 9895347 - Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis (2018-02-20),
3. 9351955 - Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis (2016-05-31),
4. 9133210 - Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis (2015-09-15),
5. 9006237 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2015-04-14),
6. 8178530 - Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2012-05-15),
7. 8173656 - Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2012-05-08),
8. 8148369 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2012-04-03),
9. 8138193 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2012-03-20),
10. 8133895 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2012-03-13),
11. 8012983 - Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases (2011-09-06),
12. 7977352 - Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases (2011-07-12),
13. 7951818 - Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases (2011-05-31),
14. 7915256 - Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2011-03-29),
15. 7893058 - Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases (2011-02-22),

Title: The Innovative Journey of Martin James Inglis Andrews

Introduction:

Martin James Inglis Andrews is a visionary inventor based in Mechelen, Belgium, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents:

Martin James Inglis Andrews holds several patents in the areas of renewable energy technologies, artificial intelligence, and sustainable transportation solutions.

Career Highlights:

With a career spanning over two decades, Martin James Inglis Andrews has worked with leading research institutions and tech companies to develop cutting-edge solutions that have revolutionized various industries.

Collaborations:

Throughout his career, Martin James Inglis Andrews has collaborated with top engineers, scientists, and designers to bring his innovative ideas to life. His collaborative spirit has led to the successful implementation of numerous projects.

Conclusion:

Martin James Inglis Andrews continues to push the boundaries of innovation, inspiring the next generation of inventors and leaving a lasting impact on the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…